By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Hutchison China MediTech (Chi-Med) 

21st Floor, Hutchison House
10 Harcourt Road
Hong Kong      China
Phone: 852-2121-8200 Fax: 852-2121-8281


Hutchison China MediTech Limited, known as Chi-Med, is an innovative biopharmaceutical company aiming to become a global leader in the discovery, development and commercialisation of targeted therapies for oncology and immunological diseases.




CEO: Christian Hogg

CFO: Johnny Cheng

CSO: Weiguo Su

Key Statistics

Ownership: Subsidiary

Web Site: Hutchison China MediTech (Chi-Med)


Company News
Hutchison China MediTech (Chi-Med)'s Innovative Drug Portfolio: Eight Candidates In 31 Trials 8/3/2017 11:12:23 AM
Hutchison China MediTech (Chi-Med) Reports 2017 Interim Results And Updates Shareholders On Key Clinical Programs 7/31/2017 7:13:45 AM
Hutchison China MediTech (Chi-Med) And AstraZeneca PLC (AZN) Initiate SAVOIR, A Global Phase III Trial Of Savolitinib In Papillary Renal Cell Carcinoma 6/29/2017 6:24:36 AM
Hutchison China MediTech (Chi-Med) To Announce 2017 Half-Year Financial Results 6/29/2017 6:21:54 AM
Hutchison China MediTech (Chi-Med) Initiates A Phase I/II Clinical Trial Of Novel FGFR Inhibitor HMPL-453 In China 6/22/2017 6:42:18 AM
Hutchison China MediTech (Chi-Med) Submits New Drug Application To CFDA For Fruquintinib In Advanced Colorectal Cancer 6/12/2017 7:06:53 AM
Hutchison China MediTech (Chi-Med) Says Fruquintinib Increased Median Survival 41% 6/6/2017 3:21:56 PM
Hutchison China MediTech (Chi-Med) Highlights Phase III Fruquintinib Data In Oral Presentation At ASCO 6/6/2017 7:54:10 AM
Hutchison China MediTech (Chi-Med) Presents Clinical Data At ASCO 2017 Annual Meeting 5/18/2017 8:15:15 AM
Hutchison China MediTech (Chi-Med) Presented Pre-Clinical Data For Fruquintinib And Sulfatinib At The AACR Annual Meeting 2017 4/7/2017 12:37:22 PM